Primary breast carcinoma en cuirasse. A rare presentation of an aggressive malignancy and review of the literature

2021 ◽  
Vol 39 (3-4) ◽  
pp. 155-159
Author(s):  
Nikolaos S. Salemis ◽  
Charalambos Christofyllakis ◽  
Kyriakos Spiliopoulos

Breast carcinoma en cuirasse is a very rare form of cutaneous metastases of breast cancer. The clinical presentation is that of a diffuse indurated carcinomatous infiltration of the skin and subcutaneous tissues of the mammary region and the anterior aspect of the chest. In most cases, breast carcinoma en cuirasse develops post-mastectomy and represents a dramatic presentation of an aggressive tumor associated with a dismal prognosis. Because of the rarity of this type of malignancy, the optimal approach to treatment has not been clearly defined. The systemic treatment has been associated with limited efficacy, and the primary goal is palliative care and preservation of the quality of life through skin-directed therapies. Herein, a very rare case of primary breast carcinoma en cuirasse is presented, along with a review of the literature. Early diagnosis and prompt treatment of any potential skin metastases of breast cancer are essential to prevent the catastrophic natural progression of the disease.

Author(s):  
Musa Azhar ◽  
Syed Abdul Mannan Hamdani ◽  
Jhanzeb Iftikhar ◽  
Waqas Ahmad ◽  
Sajid Mushtaq ◽  
...  

Breast cancer is the commonest cancer among females and has a high propensity to metastasize, but gynaecological organs are rarely affected. We report a case where invasive ductal carcinoma of the breast metastasized to the uterus after initial management with curative intent. Our patient was on tamoxifen, which can cause endometrial hyperplasia and lead to a challenge in eventual diagnosis.


2017 ◽  
Vol 10 (2) ◽  
pp. 706-712 ◽  
Author(s):  
Sondos Al Khatib ◽  
Wafa Asha ◽  
Omar Khzouz ◽  
Farid Barakat ◽  
Jamal Khader

A 54-year-old female patient, a breast cancer survivor and a case of unresectable adenoid cystic carcinoma of the trachea, with thyroid invasion, presented with suprasternal neck swelling mimicking thyroid primary. A literature search was undertaken to highlight this rare presentation. There have been few reports in the literature describing tracheal adenoid cystic carcinoma involving the thyroid.


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10631-10631
Author(s):  
Z. I. Tomasevic ◽  
D. Jovanovic ◽  
L. Radosevic-Jelic ◽  
Z. Tomasevic ◽  
S. Vasovic ◽  
...  

10631 Background: HER-2 status of the primary breast carcinoma in the subgroup of patients who relapsed after many years is not well known. The aim of this paper is to determine the HER-2 status of the primary breast cancer in patients with late relapse, defined as local recurrence, distant metastases or carcinoma in the contralateral breast, at least five years after the initial diagnosis Methods: During six month period (June-November 2005) 1256 patients were diagnosed with primary or relapsed breast cancer at the IORS. HER-2 (HercepTest, DAKO) status was determined on the archived pathological specimens of patients with late relapse. Results: One hundred eleven patients (111/1256; 8,8%) were diagnosed with late relapse. At the time of the initial diagnose, majority of patients have been treated for early breast carcinoma. Median age at the initial diagnose was 50 years (33–74). Initial tumor characteristic were: ductal carcinoma 49%; lobular carcinoma 41%;cancer mastitis 6,5%;not reported 3,5%; T1 34%; T2 52%; T3 4,5%; T4 6%;unknown 3,5%; Nodal status: positive 73,5%; negative 23%;not reported 3,5% Steroid receptor status: ER and/or PR positive 59%; both negative 14%; unknown 27%. Median time to relapse is 7 years, (range 5–29), the most frequent first relapse sites were: local recurrence (22%); carcinoma of the contralateral breast (18%); bone metastases (18%). Archived pathological specimens are identified for 63/111 (56,7%) patients and HER-2 status of the those primary breast carcinoma is: 0+ 36,5%; 1+ 34,9%; 2+ 9,5%; 3+ 14,2%; Thirty four patients (30,6%) had disease free interval 10 or more years, and HER-2 3+ in this subgroup is 17,6% (6/34). Conclusions: Long disease free interval in breast cancer patients is usually explained by initial more favorable cancer characteristics. Still, a significant percentage (14,2%) of our patients with median time to relapse of 7 years, initially had breast cancers with HER-2 3+. No significant financial relationships to disclose.


2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Raymon Patron ◽  
Edward F. Miles

Primary lymphoma of the breast is a rare entity in the field of oncological medicine and represents <0.5% of all breast malignancies. A definitive diagnosis is obtained by excisional biopsy as the clinical and radiographical presentation is similar to the more common primary breast carcinoma. Unlike primary breast carcinoma, localized radiation therapy is the mainstay of treatment. We report on a case of primary follicular lymphoma of the breast in a 67-year-old Caucasian woman treated with localized radiation as well as coinciding literature review regarding outcomes of different treatment modalities.


1988 ◽  
Vol 74 (3) ◽  
pp. 321-327 ◽  
Author(s):  
Silvana Di Palma ◽  
Salvatore Andreola ◽  
Luciano Lombardi ◽  
Claudio Colombo

We report a case of ileal carcinoid which clinically presented as a primary breast carcinoma. Review of the literature demonstrated only 9 cases of carcinoids metastatic to the breast. In spite of the rarity of this event, the differential diagnosis between primary and metastatic carcinoid of the breast should be considered in view of the different clinical management of these two settings.


2008 ◽  
Vol 159 (3) ◽  
pp. 197-202 ◽  
Author(s):  
Andreas Mueller ◽  
Louis Gooren

ObjectiveTo assess the risk of development of hormone-related tumors in transsexuals receiving treatment with cross-sex hormones.DesignDescription of cases of transsexuals who have developed a hormone-related malignancy observed in their own clinic or reported in the literature. Recommendations for early diagnosis and prevention are presented.MethodsReview of the literature in PubMed.ResultsIn male-to-female transsexuals receiving estrogen administration, lactotroph adenomas, breast cancer, and prostate cancer have been reported. In female-to-male transsexuals receiving treatment with testosterone, a single case of breast carcinoma and several cases of ovarian cancer have been reported. So far endometrial cancer has not been encountered though it remains a potential malignant development.ConclusionsThere are so far only a few cases of hormone-related cancer in transsexuals. There may be an underreporting. The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals.


Sign in / Sign up

Export Citation Format

Share Document